|By Marketwired .||
|January 23, 2014 12:40 PM EST||
MONTREAL, QUEBEC -- (Marketwired) -- 01/23/14 -- Pediapharm Inc. ("Pediapharm" or the "Corporation") (TSX VENTURE: PDP) announces that its Board of Directors has approved the grant of 3,810,000 stock options to certain directors, officers and employees of the Corporation, subject to regulatory and TSX Venture Exchange approval. The options were issued with an exercise price of $0.46 per share and have a term of ten (10) years. In addition, the options have varied vesting provisions such that they vest either over three (3) or four (4) years.
Pediapharm is the only Canadian specialty pharmaceutical company, dedicated to serving the needs of the pediatric community. Its mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. Since its debut in 2008, Pediapharm has entered into numerous commercial agreements with partners from Canada and other countries around the world. The company's innovative product portfolio includes NYDA®; a breakthrough treatment for head lice; EpiCeram® a non-steroid emulsion for eczema; KoolEffect which reduces the symptoms of fever; and VapoLyptus; a soothing vapour patch of Eucalyptus and Camphor)
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state in the United States in which such offer, solicitation or sale would be unlawful. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.